02315 百奧賽圖－Ｂ
BIOCYTOGEN-B
BIOCYTOGEN-B
| Listing Date | 2022/09/01 |
| Listing Price | 25.220 |
Quote
Subscription Result
- Subscription Rate5.93x
- Guarantee One Lot Size14 lot
- One Lot Success Rate50%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Biocytogen Pharmaceuticals (Beijing) founded in 2009, it is a biopharmaceutical and revenue-generating pre-clinical research services company. It has two Core Products, YH003 and YH001, and 10 other pipeline product candidates.
The Group’s Core Product YH003 is primarily being developed for pancreatic ductal adenocarcinoma, melanoma and other advanced solid tumors. Its other Core Product YH001 is primarily being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC) and other solid tumors. Most of its clinicalstage drug candidates, including both Core Products, are developed as combination therapies.
As of 13 Aug 2022, the Group had 258 registered trademarks, 93 registered patents and four software copyrights, and filed 283 patent applications in 17 countries or regions. It had two issued patents and 30 filed patent applications in relation to its Core Products.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 500 |
GLOBAL OFFERING
| No. of Offer Shares | 21.76M H shares |
| No. of International Offer Shares | 19.58M H shares |
| No. of HK Offer Shares | 2.18M H shares |
| Offer Price | $25.22 |
| Stock Code | 2315 |
| Sponsor(s) | Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited |
| Underwriter(s) | Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, CMB International Capital Limited, CLSA Limited, BOCOM International Securities Limited, Futu Securities International (Hong Kong) Limited, Valuable Capital Limited, Haitong International Securities Company Limited |
TIME TABLE
| Application Period | Aug 19 (Fri) - noon, Aug 24 (Wed) |
| Price Determination Date | Aug 24 (Wed) |
| Result Announcement Date | On or before Aug 31 (Wed) |
| Result Announcement Date | On or before Aug 31 (Wed) |
| Dealings in Shares commence on | Sep 01, 2022. (Thu) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $25.22 |
| Capitalization | 10.00B |
| NAV / share ($) | $4.31 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 25.22, the net proceeds raised would be HKD 471.10M, of which |
| 70% : Fund further clinical research and development of Core Products, YH003 and YH001 |
| 15% : Fund antibody drug discovery and development |
| 10% : Fund pre-clinical and clinical development of other pipeline products |
| 5% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).